https://www.selleckchem.com/products/mk-0159.html 0001), with a higher proportion of responders at each time point [75% versus 71.1% (  = 0.687) at day 1, 93.2% versus 73.7% at day 3 (  = .016) and 95.5% versus 71.1% at day 7 (  = .003)], higher values of SPID (770.9 ± 23.5 vs. 507.1 ± 22.6;  < .0001) and significantly greater reduction in DN4 score [-62.7 ± 25.6 vs. -39.7 ± 31.2 (  < .0001)]. Both treatments were well tolerated. Orally administered TRAM/DKP 75/25 mg can be a valuable and effective option in patients with acute LBP. Orally administered TRAM/DKP 75/25 mg can be a valuable and effective option in patients with acute LBP. From both a public health and economic perspective, vaccination is arguably the most effective approach to combat endemic and pandemic infectious diseases. Dengue affects more than 100 countries in the tropical and subtropical world, with 100-400 million infections every year. In the wake of the recent setback faced by Dengvaxia, the only FDA-approved dengue vaccine, safer and more effective dengue vaccines candidates are moving along the clinical pipeline. This review provides an update of the latest outcomes of dengue vaccine clinical trials. In the light of recent progress made in our understanding of dengue pathogenesis and immune correlates of protection, novel vaccine strategies have emerged with promising second-generation dengue vaccine candidates. Finally, the authors discuss the dengue-specific challenges that remain to be addressed and overcome. The authors propose to explore various adjuvants and delivery systems that may help improve the design of safe, effective, and affordable vaccines against dengue. They also challenge the concept of a 'universal' dengue vaccine as increasing evidence support that DENV strains have evolved different virulence mechanisms. The authors propose to explore various adjuvants and delivery systems that may help improve the design of safe, effective, and affordable vaccines against dengue. The